NAARDEN, The Netherlands & OSLO, Norway--(BUSINESS WIRE)--Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a DAMP protein implicated in severe, life-threatening fibrotic diseases CAL101 being investigated in Phase 2 IPF Study; enrollment ...

Calluna Pharma has concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and fibro-inflammatory indications. CAL101 is a first-in-class monoclonal antibody (mAb) targeting the ...

Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...

Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that Gijs van den Brink, MD, PhD, has been ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their ...

New company to complete multiple clinical proofs-of-concept, across programs Series A led by Forbion, with participation from Norwegian investors Sarsia, p53, and Investinor NAARDEN, The Netherlands & ...